Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynie L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ
Nat Commun. 2021 Sep 22;12(1):5469. doi: 10.1038/s41467-021-25480-z.
PubMed Article

Plasmids from Article

ID Plasmid Purpose
171924pOPINO_C1Bacterial expression of nanobody VHH_C1, which binds to receptor binding domain of the spike protein of SARS-CoV-2
171925pOPINO_C5Bacterial expression of nanobody VHH_C5, which binds to receptor binding domain of the spike protein of SARS-CoV-2
171926pOPINO_F2Bacterial expression of nanobody VHH_F2, which binds to receptor binding domain of the spike protein of SARS-CoV-2
171927pOPINO_H3Bacterial expression of nanobody VHH_H3, which binds to receptor binding domain of the spike protein of SARS-CoV-2

Antibodies from Article